Press releasePRNewswire
Transcode Therapeutics
RNAZ · NASDAQ
$1.68−$0.02 (−1.18%)TodayMarket closed ·
Prev close $1.70
Latest news
- Press releaseBusiness Wire
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
- Press releasePRNewswire
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
- Press releasePRNewswire
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
- Press releasePRNewswire
TransCode Therapeutics Announces Leadership Transition
- Press releasePRNewswire
TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releasePRNewswire
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
- Press releasePRNewswire
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
- Press releasePRNewswire
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
- Press releasePRNewswire
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
- Press releasePRNewswire
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
- Press releasePRNewswire
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
- Press releasePRNewswire
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releasePRNewswire
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
- Press releasePRNewswire
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
- Press releasePRNewswire
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
- Press releasePRNewswire
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
- Press releasePRNewswire
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
- Press releasePRNewswire
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
- Press releasePRNewswire
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
- NewsAvi Kapoor
Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
- Press releasePRNewswire
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
- Press releasePRNewswire
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsRishabh Mishra
US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert
- NewsAvi Kapoor
Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday
- Press releasePRNewswire
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.